CR Group L.P. 4/A
4/A · T2 Biosystems, Inc. · Filed Jul 14, 2023
Insider Transaction Report
Form 4/AAmended
Capital Royalty L.P.
10% Owner
Transactions
- Award
Series B Convertible Preferred Stock
2023-07-03+33,595→ 33,595 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.)Exercise: $0.07→ Common Stock (33,595,000 underlying) - Award
Series B Convertible Preferred Stock
2023-07-03+59,703→ 59,703 total(indirect: By CRG Partners III Parallel Fund (B) (Cayman) L.P.)Exercise: $0.07→ Common Stock (59,703,000 underlying)
Footnotes (3)
- [F1]The acquisition of these shares was inadvertently omitted from the reporting persons' Form 4 filed with the SEC on July 6, 2023.
- [F2]Each share of Series B Convertible Preferred Stock (the "Series B Preferred") converts into 1,000 shares of the Company's common stock at the holder's election, subject to beneficial ownership limitations, including that a holder of Series B Preferred is prohibited from converting such shares into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. As a result of the 19.99% beneficial ownership limitation, as of July 3, 2023, the Series B Preferred held by the reporting persons can be converted into a maximum of 24,157,794 shares of common stock in the aggregate. The shares of Series B Preferred have no expiration date.
- [F3]Pursuant to that certain Securities Purchase Agreement, dated July 3, 2023, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund "A" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund "B" (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt.